Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1476-1487

  Kreitman, Robert J ^a   Margulies, Inger ^a   Stetler Stevenson, Maryalice ^a   Wang, Qing Cheng ^a   FitzGerald, David J P ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; DISULFIDE; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PSEUDOMONAS EXOTOXIN;

ARTICLE; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BINDING SITES; CELL ADHESION MOLECULES; CELL DEATH; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DISULFIDES; DNA, RECOMBINANT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; INHIBITORY CONCENTRATION 50; LECTINS; LEUKEMIA, B-CELL; LEUKOCYTES, MONONUCLEAR; MUTATION; PLASMIDS; PROTEIN BIOSYNTHESIS; PROTEINS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034048735     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer Statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J., and Thorpe, P. E. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res., 51: 4052-4058, 1991.
3. Clark, E. A. CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J. Immunol., 150: 4715-4718, 1993.
4. Ghetie, M.-A., Richardson, J., Tucker, T., Jones, D., Uhr, J. W., and Vitetta, E. S. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res., 51: 5876-5880, 1991.
5. Kreitman, R. J., Hansen, H. J., Jones, A. L., FitzGerald, D. J. P., Goldenberg, D. M., and Pastan, I. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res., 53: 819-825, 1993.
6. Amlot, P. L., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramilo, O., Thorpe, P. E., Uhr, J. W., and Vitetta, E. S. A Phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624-2633, 1993.
7. Sausville, E. A., Headlee, D., Stetler-Stevenson, M., Jaffe, E. S., Solomon, D., Figg, W. D., Herdt, J., Kopp, W. C., Rager, H., Steinberg, S. M., Ghetie, V., Schindler, J., Uhr, J., Wittes, R. E., and Vitetta, E. S. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a Phase I study. Blood, 85: 3457-3465, 1995.
8. Soler-Rodriguez, A-M., Ghetie, M-A., Oppenheimer-Marks, N., Uhr, J. W., and Vitetta, E. S. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res., 206; 227-234, 1993.
9. Y damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin. Cancer Res., 1: 1589-1594, 1995.
10. Theuer, C. P., Kreitman, R. J., FitzGerald, D. J., and Pastan, I. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. Cancer Res., 53: 340-347, 1993.
11. Mansfield, E., Pastan, I., and FitzGerald, D. J. Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. Bioconjugate Chem., 7: 557-563, 1996.
12. Reiter, Y., Brinkmann, U., Kreitman, R. J., Jung, S-H., Lee, B., and Pastan, I. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry, 33: 5451-5459, 1994.
13. Reiter, Y., Kreitman, R. J., Brinkmann, U., and Pastan, I. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int. J. Cancer, 58: 142-149, 1994.
14. Mansfield, E., Amlot, P., Pastan, I., and FitzGerald, D. J. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood, 90: 2020-2026, 1997.
15. Allured, V. S., Collier, R. J., Carroll, S. F., and McKay, D. B. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Angstrom resolution. Proc. Natl. Acad. Sci. USA, 83: 1320-1324, 1986.
16. Hessler, J. L., and Kreitman, R. J. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry, 36: 14577-14582, 1997.
17. Chiron, M. F., Fryling, C. M., and FitzGerald, D. J. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J. Biol. Chem., 269: 18167-18176, 1994.
18. 280 generates the enzymatically active fragment which translocates to the cytosol. J. Biol. Chem., 267: 25396-25401, 1992.
19. Kreitman, R. J., and Pastan, I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem. J., 307: 29-37, 1995.
20. Theuer, C., Kasturi, S., and Pastan, I. Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. Biochemistry, 33: 5894-5900, 1994.
21. Theuer, C. P., Buchner, J., FitzGerald, D., and Pastan, I. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proc. Natl. Acad. Sci. USA, 90: 7774-7778, 1993.
22. Kreitman, R. J., Wang, Q. C., FitzGerald, D. J. P., and Pastan, I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus monkeys. Int. J. Cancer, 81: 148-155, 1999.
23. Kreitman, R. J., Chaudhary, V. K., Kozak, R. W., FitzGerald, D. J. P., Waldmann, T. A., and Pastan, I. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood, 80: 2344-2352, 1992.
24. Kreitman, R. J., Batra, J. K., Seetharam, S., Chaudhary, V. K., FitzGerald, D. J., and Pastan, I. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconjugate Chem., 4: 112-120, 1993.
25. Rajagopal, V., Pastan, I., and Kreitman, R. J. A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs. Protein Eng., 10: 1453-1459, 1997.
26. Benhar, I., and Pastan, I. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: Single-chain and disulfide-stabilized Fv Immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Clin. Cancer Res., 1: 1023-1029, 1995.
27. Shen, G., Li, J., Ghetie, M., Ghetie, V., May, R. D., Till, M., Brown, A. N., Relf, M., Knowles, P., Uhr, J. W., Janossy, G., Amlot, P., Vitetta, E. S., and Thorpe, P. E. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int. J. Cancer, 42: 792-797, 1988.
28. Mohammad, R. M., Mohamed, A. N., Hamdan, M. Y., Vo, T., Chen, B., Katato, K., Abubakr, Y. A., Dugan, M. C., and al-Katib, A. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia, 10: 130-137, 1996.
29. Seetharam, S., Chaudhary, V. K., FitzGerald, D., and Pastan, I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem., 266: 17376-17381, 1991.
30. Kreitman, R. J., Chaudhary, V. K., Waldmann, T. A., Hanchard, B., Cranston, B., FitzGerald, D. J. P., and Pastan, I. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia, 7: 553-562, 1993.
31. Kreitman, R. J., Wilson, W. H., Robbins, D., Margulies, I., Stetler-Stevenson, M., Waldmann, T. A., and Pastan, I. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood. 94: 3340-3348, 1999.
32. Bregni, M., Siena, S., Formosa, A., Lappi, D. A., Martineau, D., Malavasi, F., Dorken, B., Bonadonna, G., and Gianni, A. M. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells. Blood, 73: 753-762, 1989.
33. Pai, L. H., Wittes, R., Setser, A., Willingham, M. C., and Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med., 2: 350-353, 1996.
34. Reiter, Y., Brinkmann, U., Jung, S., Lee, B., Kasprzyk, P. G., King, C. R., and Pastan, I. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem., 269: 18327-18331, 1994.
35. Kreitman, R. J., Bailon, P., Chaudhary, V. K., FitzGerald, D. J. P., and Pastan, I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood, 83: 426-434, 1994.
36. Benhar, I., Reiter, Y., Pai, L. H., and Pastan, I. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int. J. Cancer, 62: 351-355, 1995.
37. Grossbard, M. L., Lambert, J. M., Goldmacher, V. S., Spector, N. L., Kinsella, J., Eliseo, L., Coral, F., Taylor, J. A., Blattler, W. A., Epstein, C. L., and Nadler, L. M. Anti-B4-blocked ricin: a Phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol., 11: 726-737, 1993.